Treatment with Brentuximab Vedotin Prior to Reduced Intensity Allogeneic HCT in Relapsed/Refractory HL
Chen RW et al. Brentuximab vedotin (SGN-35) enables successful reduced intensity allogeneic hematopoietic cell transplantation in relapsed/refractory Hodgkin lymphoma. Proc ASH 2011;Abstract 664.
Dr Moskowitz is Clinical Director in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.
|